ArticleInfection and drug resistance2019
Talaromycosis-Associated Secondary Hemophagocytic Lymphohistiocytosis in Nine Human Immunodeficiency Virus-Negative Patients: A Multicenter Retrospective Study.
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Multiple recurrences of Talaromyces marneffei infection with HLH in an HIV-negative patient: a case report.BMC infectious diseases · 2026Article
- Advanced HIV Presenting With Pancytopenia and HLH-Like Hyperinflammation Secondary to Disseminated Talaromycosis: A Case Report.Case reports in infectious diseases · 2026Article
- Fungal-Induced Hemophagocytic Lymphohistiocytosis: A Literature Review in Non-HIV Populations.Journal of fungi (Basel, Switzerland) · 2025Review
- Case Report:Frontiers in pediatrics · 2025Article
- Characteristics and risk factors for death in HIV-positive talaromycosis marneffei patients with sepsis.Heliyon · 2024Article
- Article
- The microbial damage and host response framework: lesson learned from pathogenic survival trajectories and immunoinflammatory responses ofFrontiers in immunology · 2024Review
- Talaromyces marneffei infection and complicate manifestation of respiratory system in HIV-negative children.BMC pulmonary medicine · 2023Article
- Rare incidence of non-secretory myeloma with talaromycosis: a case report.BMC infectious diseases · 2021Article
- The Presence of Secondary Evans Syndrome in AIDS Patients withInfection and drug resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePATIENTS AND
methodsThis retrospective study was conducted between August 2012 and February 2019 at multiple research centers. Patients who presented with culture and/or histopathological proof of talaromycosis-associated HLH were included.
resultsHIV-negative patients (n = 126) were enrolled. Of nine patients with T.M infection combined with secondary HLH, six were preschool children (five boys and one girl), and three were adults (two men and one woman). Seven of these nine had underlying diseases or recurrent infections. The most common symptoms were fever, anemia, hypoproteinemia, cough, weight loss, oral thrush, lymphadenopathy, hepatomegaly, splenomegaly, digestive symptoms, joint pain, and dyspnea. All patients showed reduced hemoglobin concentrations and platelet numbers. Liver dysfunction, hyperferritinemia, elevated lactate dehydrogenase, and low natural killer cell numbers were observed. Eight of nine patients received antifungal therapy, one patient did not receive therapy, and two of nine patients received anti-HLH therapy. Four died during treatment.
conclusionT.M fungemia associated with HLH was related to high mortality. Once diagnosed, timely and effective antifungal treatments and supportive care are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.